Search
Search Results
##search.searchResults.foundPlural##
-
Peripheral Red Blood Cell Split Chimerism as a Consequence of Intramedullary Selective Apoptosis of Recipient Red Blood Cells in a Case of Sickle Cell Disease
1762PDF: 1063HTML: 1896Untitled: 245Untitled: 222 -
-
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
7160PDF: 3801HTML: 845 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4604Suppl. Files: 1252PDF: 1155Html: 311 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3940PDF: 1574HTML: 355 -
THE ROLE OF INFECTION IN THE PATHOGENESIS OF VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE.
5513PDF: 1412HTML: 2881Cover letter: 247 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2653PDF: 1793HTML: 698 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4661PDF: 1811HTML: 1319 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2389PDF: 998HTML: 2377 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1891PDF: 938HTML: 1541 -
NEW STRATEGIES FOR STEM CELL MOBILIZATION
2581PDF: 953HTML: 2581 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2708PDF: 937HTML: 17607Fig1 Caligaris: 232Fig.2 Caliga: 272 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2416PDF: 2149HTML: 234 -
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2405PDF: 1889HTML: 1011 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1196PDF: 1236Suppl. Files: 600HTML: 105 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3310PDF: 1199HTML: 1694Untitled: 221Untitled: 224Untitled: 212 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2653PDF: 900HTML: 9069Efremov 1: 273Efremov 2: 242 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3911PDF: 1710HTML: 104 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3235PDF: 952HTML: 7316Kost Fig1: 230Kost Fig 2: 217Kost Fig3: 230Kost Fig 4: 242Kost Fig5: 237Kost fig 6: 226 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
3052PDF: 1173HTML: 135 -
How I treat acute and persistent sickle cell pain
2127PDF: 1185HTML: 793 -
-
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2966PDF: 1222HTML: 11431 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3908PDF: 1688HTML: 877Figures . Eliassian: 288 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3772PDF: 2633HTML: 1674 -
IMMUNOLOGY OF TUBERCULOSIS
5883PDF: 2277HTML: 7370Untitled: 247 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3412PDF: 1563HTML: 5973Fig1-Ag-Pil: 284Ag-Pil Fig.2: 284 -
VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS
3926PDF: 1669HTML: 8254Randi Fig: 229 -
SICKLE CELL ANAEMIA AND MALARIA
11913PDF: 7346HTML: 24080Figures Malaria and SCK: 273 -
-
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2703PDF: 869HTML: 5388 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2318PDF: 1050HTML: 1992 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2450PDF: 1387HTML: 17221Bassan Fig.1: 182Bassan Fig.2: 286Bassan Fig.4: 172Fig.3: 266







